The UPC: a new rocket docket for life sciences patent litigation

We recently contributed to a special report on life sciences IP strategy published by Intellectual Asset Management (IAM).

The report, New Dawn for Life Sciences IP Strategy, provides insight into the areas where life sciences IP strategy is being reshaped most radically. Paul England and Anja Lunze share their expert views in a section dedicated to shifts in the legal and regulatory landscape; The UPC: a new rocket docket for life sciences patent litigation. They discuss that despite expectations that life sciences patentees would avoid the UPC, the new court has already made its mark on healthcare-related patent strategies, while pharma and medical device cases are helping to shape UPC case law. 

Read the full report